Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients: absence of detectable receptor correlates with resistance to corticotherapy - PubMed (original) (raw)
Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients: absence of detectable receptor correlates with resistance to corticotherapy
L Prin et al. Clin Exp Immunol. 1989 Dec.
Abstract
Assessment of steroid receptor content in human neoplastic lymphoid cells or mammary tumour cells has been previously used to predict steroid sensitivity in various types of cancers. In the present study, we have evaluated the relationship between glucocorticoid receptor content and the glucocorticoid sensitivity of human eosinophils, since hypereosinophilic patients do not always respond favourably to glucocorticoid, particularly in the hypereosinophilic syndrome (HES). Blood or alveolar eosinophils obtained from seven patients (four with HES without leukaemic markers; two with parasitic diseases; and one with eosinophilic pneumonia) displayed the same specific glucocorticoid receptor content as normal eosinophils (7.58 +/- 1.31 x 10(3) versus 7.76 +/- 0.74 x 10(3) sites/cell). In contrast, glucocorticoid-binding sites were undetectable in purified eosinophils collected from seven HES patients with (n = 3) or without (n = 4) leukaemic markers, whilst their mononuclear cells and/or neutrophils bound glucocorticoid. In one HES patient, kinetic studies showed that blood eosinophils initially positive in glucocorticoid binding assays became negative with the subsequent appearance of leukaemic markers. The absence of specific glucocorticoid binding sites was correlated with the absence of glucocorticoid receptor proteins by the use of a specific anti-glucocorticoid receptor monoclonal antibody. Eosinophil sensitivity to glucocorticoid was investigated by the evaluation of glucocorticoid inhibition of eosinophil chemotaxis and by the clinical outcome of in vivo glucocorticoid therapy. Our data provide evidence of the heterogeneity of eosinophil glucocorticoid receptor expression. In addition, the presence of glucocorticoid receptors is a prerequisite for glucocorticoid activity, in vitro and in vivo, on cells of the eosinophil lineage.
Similar articles
- Mechanisms of glucocorticoid resistance in hypereosinophilic syndromes.
Stokes K, Yoon P, Makiya M, Gebreegziabher M, Holland-Thomas N, Ware J, Wetzler L, Khoury P, Klion AD. Stokes K, et al. Clin Exp Allergy. 2019 Dec;49(12):1598-1604. doi: 10.1111/cea.13509. Epub 2019 Oct 27. Clin Exp Allergy. 2019. PMID: 31657082 Free PMC article. Clinical Trial. - [An anti-human eosinophil monoclonal antibody AE500 that reacts only with granulocytes from hypereosinophilic patients].
Ochiai K, Iwamoto I, Kimura A, Nakagawa N, Tomioka H, Yoshida S, Takahashi H, Yoshida A. Ochiai K, et al. Arerugi. 1990 May;39(5):459-64. Arerugi. 1990. PMID: 2393351 Japanese. - The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders.
Legrand F, Tomasevic N, Simakova O, Lee CC, Wang Z, Raffeld M, Makiya MA, Palath V, Leung J, Baer M, Yarranton G, Maric I, Bebbington C, Klion AD. Legrand F, et al. J Allergy Clin Immunol. 2014 May;133(5):1439-47, 1447.e1-8. doi: 10.1016/j.jaci.2013.11.041. Epub 2014 Feb 13. J Allergy Clin Immunol. 2014. PMID: 24530099 Free PMC article. Clinical Trial. - Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.
Butterfield JH. Butterfield JH. Acta Haematol. 2005;114(1):26-40. doi: 10.1159/000085560. Acta Haematol. 2005. PMID: 15995323 Review. - World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J. Gotlib J. Am J Hematol. 2015 Nov;90(11):1077-89. doi: 10.1002/ajh.24196. Am J Hematol. 2015. PMID: 26486351 Review.
Cited by
- Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis.
Nguyen L, Saha A, Kuykendall A, Zhang L. Nguyen L, et al. Cancers (Basel). 2024 Mar 31;16(7):1383. doi: 10.3390/cancers16071383. Cancers (Basel). 2024. PMID: 38611061 Free PMC article. Review. - Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.
Valent P, Degenfeld-Schonburg L, Sadovnik I, Horny HP, Arock M, Simon HU, Reiter A, Bochner BS. Valent P, et al. Semin Immunopathol. 2021 Jun;43(3):423-438. doi: 10.1007/s00281-021-00863-y. Epub 2021 May 30. Semin Immunopathol. 2021. PMID: 34052871 Free PMC article. Review. - Mechanisms of glucocorticoid resistance in hypereosinophilic syndromes.
Stokes K, Yoon P, Makiya M, Gebreegziabher M, Holland-Thomas N, Ware J, Wetzler L, Khoury P, Klion AD. Stokes K, et al. Clin Exp Allergy. 2019 Dec;49(12):1598-1604. doi: 10.1111/cea.13509. Epub 2019 Oct 27. Clin Exp Allergy. 2019. PMID: 31657082 Free PMC article. Clinical Trial. - Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids.
Khoury P, Abiodun AO, Holland-Thomas N, Fay MP, Klion AD. Khoury P, et al. J Allergy Clin Immunol Pract. 2018 Jan-Feb;6(1):190-195. doi: 10.1016/j.jaip.2017.06.006. Epub 2017 Jul 27. J Allergy Clin Immunol Pract. 2018. PMID: 28757367 Free PMC article. Clinical Trial. - Novel Therapies for Eosinophilic Disorders.
Bochner BS. Bochner BS. Immunol Allergy Clin North Am. 2015 Aug;35(3):577-98. doi: 10.1016/j.iac.2015.05.007. Immunol Allergy Clin North Am. 2015. PMID: 26209901 Free PMC article. Review.
References
- Blood. 1987 Sep;70(3):860-8 - PubMed
- Blood. 1981 Nov;58(5):1021-6 - PubMed
- J Exp Med. 1985 Jul 1;162(1):60-74 - PubMed
- Am J Med. 1987 Mar;82(3):539-45 - PubMed
- J Allergy Clin Immunol. 1986 Sep;78(3 Pt 1):450-7 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical